Glecaprevir, an NS3/4A protease inhibitor, is used in combination with pibrentasvir for individuals infected with all the genotypes (1 to 6) of HCV, without cirrhosis or compensated cirrhosis, and for those patients infected with HCV genotype 1 who have previously received an NS3/4A or NS5A DAA [90]. The gene discussed is KRAS; the disease is Cirrhosis.